DIVERSITY OF CTL EPITOPES AND CHLAMYDIA

CTL 表位和衣原体的多样性

• 批准号: 6356479
• 负责人: MARY F LAMPE
• 金额: $ 15.29万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-15 至 2001-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6356479
• 关键词: Bacillus; Chlamydia trachomatis; MHC class I antigen; bacterial antigens; bacterial toxins; bacterial vaccines; cellular immunity; cooperative study; cytotoxic T lymphocyte; epitope mapping; immunoconjugates; laboratory mouse; sexually transmitted diseases; vaccine development

Chlamydia is the most prevalent cause of bacterial sexually transmitted disease in the developed world, Causing both overt disease and infertility, and is also the leading cause of preventable blindness worldwide. Natural immunity against Chlamydia and the vaccine strategies that have been attempted to date provide protection against only limited serovars. The goal of these studies is to ascertain whether a vaccine strategy which primes a cytotoxic T-lymphocyte (CTL) response can provide protection against a wide range of Chlamydia serovars. We have cultured Chlamydia reactive CTL from infected mice and have shown that they are specific for and lyse Chlamydia infected cells in vitro. Upon adoptive transfer of these CTL into Chlamydia infected mice, a reduction in bacterial load can be measured in the spleen. The initial experiments in this proposal will determine whether CTL specific for Chlamydia can be primed in mice of different MHC haplotypes. Other experiments characterize the diversity of antigens recognized by Chlamydia specific CTL and whether the diversity of antigens recognized by CTL primed by genital infection differ from those primed intraperitoneally. Thirdly, we propose to determine which of these antigens can prime CTL which are both protective and cross-reactive between Chlamydia serovars. This project will contribute to the overall program by characterizing at the cellular and molecular level antigens which are important in a protective CTL response. The project will complement project 3 which proposes in part to examine the CTL response elicited by Chlamydia infection in humans. This project is dependent on the resources provided by the laboratory (D) and statistical (B) cores. By providing novel information about the protective CTL response engendered during Chlamydia STD, this project will contribute to the overall objective of developing a vaccine to prevent and control these infections.

衣原体是细菌性传播最常见的原因 发达国家的疾病，既造成明显的疾病， 不孕症，也是可预防的失明的主要原因 国际吧衣原体的天然免疫及疫苗策略 迄今为止，已经尝试提供保护， 血清型这些研究的目的是确定疫苗是否 引发细胞毒性T淋巴细胞（CTL）应答的策略可以提供 保护免受各种衣原体血清型。我们培养了 衣原体反应性CTL从感染的小鼠，并已表明，他们是 特异于并在体外裂解衣原体感染的细胞。收养后 将这些CTL转移到衣原体感染的小鼠中， 可以在脾中测量细菌负荷。最初的实验， 这项建议将决定是否可以用特异性的衣原体CTL， 在不同MHC单倍型的小鼠中引发。其他实验 表征衣原体特异性抗原识别的多样性 CTL和是否由CTL识别的抗原的多样性引发的 生殖器感染与腹腔内感染不同。第三， 我们建议确定这些抗原中的哪一种可以引发CTL， 在衣原体血清型之间既有保护性又有交叉反应性。 该项目将有助于整体方案的特点， 细胞和分子水平的抗原，这是重要的， 保护性CTL应答。该项目将补充项目3， 提出部分检查衣原体引起的CTL反应 人类感染。该项目取决于提供的资源 实验室（D）和统计（B）核心。通过提供新型 关于衣原体感染过程中产生的保护性CTL反应的信息 该项目将有助于实现 预防和控制这些感染的疫苗。